A NEW drug could slash the risk of heart attacks or strokes for victims of Type 2 diabetes, it has been revealed.
The revolutionary new treatment could help the thousands of patients who do not respond to the commonly used first-line treatment, metformin.
According to an article published online in The Lancet, metformin can become ineffective in the long term for many patients.
Patients are then offered a class of drugs known as sulphonylureas in addition.
However, these drugs can lead to low blood sugar levels, known as hypoglycaemia, and weight gain, putting patients at increased risk of heart attack and stroke.
The new drug, linagliptin, results in significantly less weight gain and also less hypoglycaemia, research by experts from Tübingen University Hospital, in Germany, has shown.
In another development, a ground-breaking study has found that stem cells treatment could be used to reverse Type 1 diabetes by restoring natural insulin production.
Diabetic mice were weaned off insulin injections after stem cell transplant and were able to maintain healthy blood sugar levels, says research carried out by New Jersey-based BetaLogics in the US and published in the journal Diabetes.